

Maija HollmÄ©n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3951976/publications.pdf>

Version: 2024-02-01

58
papers

2,402
citations

257450
24
h-index

214800
47
g-index

65
all docs

65
docs citations

65
times ranked

4320
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonclinical Characterization of Bexmarilimab, a Clev-1-Targeting Antibody for Supporting Immune Defense Against Cancers. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1207-1218.	4.1	5
2	Novel Biomarkers for Diagnosing Periprosthetic Joint Infection from Synovial Fluid and Serum. <i>JBJS Open Access</i> , 2021, 6, .	1.5	11
3	Vascular Adhesion Protein 1 Mediates Gut Microbial Flagellin-Induced Inflammation, Leukocyte Infiltration, and Hepatic Steatosis. <i>Sci</i> , 2021, 3, 13.	3.0	3
4	A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status without Significant Changes in the Lipid Composition Characterizes Lipedema. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3313.	4.1	18
5	Lymphatic Endothelial Cell Activation and Dendritic Cell Transmigration Is Modified by Genetic Deletion of Clev-1. <i>Frontiers in Immunology</i> , 2021, 12, 602122.	4.8	22
6	Intravenous Interferon- γ 1a for the Treatment of Ischemia-Reperfusion Injury in Acute Myocardial Infarct in Pigs. <i>Heart Surgery Forum</i> , 2021, 24, E409-E413.	0.5	0
7	Systemic Blockade of Clev-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4205-4220.	7.0	29
8	LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types. <i>Annals of Oncology</i> , 2021, 32, S1313.	1.2	2
9	Vascular adhesion protein-1 defines a unique subpopulation of human hematopoietic stem cells and regulates their proliferation. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7851-7872.	5.4	1
10	Melanocortin 1 Receptor Deficiency in Hematopoietic Cells Promotes the Expansion of Inflammatory Leukocytes in Atherosclerotic Mice. <i>Frontiers in Immunology</i> , 2021, 12, 774013.	4.8	8
11	Red blood cell transfusion induces abnormal HIF-1 α response to cytokine storm after adult cardiac surgery. <i>Scientific Reports</i> , 2021, 11, 22230.	3.3	5
12	Metastable Atrial State Underlies the Primary Genetic Substrate for MYL4 Mutation-Associated Atrial Fibrillation. <i>Circulation</i> , 2020, 141, 301-312.	1.6	28
13	1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clev-1 blockade in advanced cancer. <i>Annals of Oncology</i> , 2020, 31, S706-S707.	1.2	1
14	Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. <i>Intensive Care Medicine</i> , 2020, 46, 1937-1940.	8.2	29
15	Adipose Tissue Hypertrophy, An Aberrant Biochemical Profile and Distinct Gene Expression in Lipedema. <i>Journal of Surgical Research</i> , 2020, 253, 294-303.	1.6	48
16	Interferon beta-1a for COVID-19: critical importance of the administration route. <i>Critical Care</i> , 2020, 24, 335.	5.8	35
17	New tools to prevent cancer growth and spread: a "Clever" approach. <i>British Journal of Cancer</i> , 2020, 123, 501-509.	6.4	34
18	Increased levels of VEGF-C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology. <i>Scientific Reports</i> , 2020, 10, 10947.	3.3	34

#	ARTICLE	IF	CITATIONS
19	Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.. Journal of Clinical Oncology, 2020, 38, 3097-3097.	1.6	7
20	Ex Vivo Modelling of Therapy Efficacy for Rare Krukenberg Tumors – A Report of Two Cases. Clinical Oncology and Research, 2020, , 1-8.	0.0	1
21	Abstract 16742: Single-Cell Transcriptional and Epigenomic Dissection of Human Heart in Health and Coronary Artery Disease Reveals Cell-type-Specific Driver Genes and Pathways. Circulation, 2020, 142, .	1.6	0
22	Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils. Immunity, 2019, 51, 561-572.e5.	14.3	149
23	Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours. Annals of Oncology, 2019, 30, v865-v866.	1.2	5
24	Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science Immunology, 2019, 4, .	11.9	13
25	Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors. Clinical Cancer Research, 2019, 25, 3289-3303.	7.0	73
26	Editorial: Targeting Myeloid Cells to Fight Cancer. Frontiers in Immunology, 2019, 10, 2835.	4.8	2
27	Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis. Cytokine, 2019, 114, 74-80.	3.2	7
28	Melanocortin 1 Receptor Deficiency Promotes Atherosclerosis in Apolipoprotein E ^{0/0} Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 313-323.	2.4	22
29	P1655Preoperative predictors for systemic inflammatory response in open-heart surgery. European Heart Journal, 2018, 39, .	2.2	0
30	Enhanced Antibody Production in Clever-1/Stabilin-1 Deficient Mice. Frontiers in Immunology, 2018, 9, 2257.	4.8	12
31	Six-Week Endurance Exercise Alters Gut Metagenome That Is not Reflected in Systemic Metabolism in Over-weight Women. Frontiers in Microbiology, 2018, 9, 2323.	3.5	145
32	Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice. PLoS ONE, 2018, 13, e0198262.	2.5	22
33	Abstract 4744: Disruption of Clever-1 in macrophages activates the innate immune response and mediates tumor rejection. , 2018, , .		1
34	Abstract 4740: CLEVER-1 as a marker to identify breast cancer patients under immunosuppression. , 2018, , .		0
35	Regulation of CD73 in the development of lower limb atherosclerosis. Purinergic Signalling, 2017, 13, 127-134.	2.2	10
36	New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. Oncotarget, 2017, 8, 1007-1022.	1.8	22

#	ARTICLE	IF	CITATIONS
37	Compared to Intermittant Claudication Critical Limb Ischemia Is Associated with Elevated Levels of Cytokines. PLoS ONE, 2016, 11, e0162353.	2.5	24
38	Transcriptional profiling of macrophage and tumor cell interactions in vitro. Genomics Data, 2016, 8, 1-3.	1.3	5
39	Transgenic overexpression of VEGF-C induces weight gain and insulin resistance in mice. Scientific Reports, 2016, 6, 31566.	3.3	52
40	G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. OncoImmunology, 2016, 5, e1115177.	4.6	123
41	Soluble CD73 in Critically Ill Septic Patients – Data from the Prospective FINNAKI Study. PLoS ONE, 2016, 11, e0164420.	2.5	7
42	Lymphatic endothelial cells attenuate inflammation via suppression of dendritic cell maturation. Oncotarget, 2016, 7, 39421-39435.	1.8	60
43	Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. European Journal of Immunology, 2015, 45, 562-573.	2.9	25
44	Pharmakokinetik von Medikamenten durch Echtzeit-Analyse der Atemluft von Mäusen. Angewandte Chemie, 2015, 127, 7926-7929.	2.0	2
45	Drug Pharmacokinetics Determined by Real-Time Analysis of Mouse Breath. Angewandte Chemie - International Edition, 2015, 54, 7815-7818.	13.8	55
46	Aberrant Circulating Levels of Purinergic Signaling Markers Are Associated With Several Key Aspects of Peripheral Atherosclerosis and Thrombosis. Circulation Research, 2015, 116, 1206-1215.	4.5	42
47	Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Scientific Reports, 2015, 5, 9188.	3.3	119
48	Blockade of VEGF-C and VEGF-D modulates adipose tissue inflammation and improves metabolic parameters under high-fat diet. Molecular Metabolism, 2015, 4, 93-105.	6.5	105
49	Cleaver-1/Stabilin-1 Controls Cancer Growth and Metastasis. Clinical Cancer Research, 2014, 20, 6452-6464.	7.0	75
50	Fingerprinting Breast Cancer vs. Normal Mammary Cells by Mass Spectrometric Analysis of Volatiles. Scientific Reports, 2014, 4, 5196.	3.3	20
51	The Orphan Adhesion G Protein-coupled Receptor GPR97 Regulates Migration of Lymphatic Endothelial Cells via the Small GTPases RhoA and Cdc42. Journal of Biological Chemistry, 2013, 288, 35736-35748.	3.4	49
52	Proteolytic Processing of ErbB4 in Breast Cancer. PLoS ONE, 2012, 7, e39413.	2.5	37
53	Abstract B187: ErbB4 ectodomain as a biomarker and a potential therapeutic target for breast cancer... , 2011, , .		0
54	Potential of ErbB4 antibodies for cancer therapy. Future Oncology, 2010, 6, 37-53.	2.4	31

#	ARTICLE	IF	CITATIONS
55	Somatic Mutations of ErbB4. Journal of Biological Chemistry, 2009, 284, 5582-5591.	3.4	55
56	Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene, 2009, 28, 1309-1319.	5.9	54
57	Pim-1 Kinase Expression Predicts Radiation Response in Squamocellular Carcinoma of Head and Neck and Is under the Control of Epidermal Growth Factor Receptor. Neoplasia, 2009, 11, 629-IN1.	5.3	65
58	Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II α gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of Oncology, 2005, 16, 273-278.	1.2	585